

INTROGEN THERAPEUTICS INC  
Form S-8 POS  
March 09, 2009

As filed with the Securities and Exchange Commission on March 9, 2009  
Registration No. 333-152912

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
POST-EFFECTIVE AMENDMENT NO. 1  
TO  
FORM S-8  
REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933  
Introgen Therapeutics, Inc.  
(Exact name of registrant as specified in its charter)**

**Delaware**  
(State or other jurisdiction of  
incorporation)

**74-2704230**  
(IRS Employer  
Identification No.)

**301 Congress Avenue, Suite 1850  
Austin, Texas 78701  
(512) 708-9310**

(Address, including zip code, and telephone number, including area code, of  
Registrant's principal executive offices)

**2000 STOCK OPTION PLAN  
(Full title of the plan)**

**J. David Enloe, Jr.  
Chief Executive Officer  
INTROGEN THERAPEUTICS, INC.  
301 Congress Avenue, Suite 1850  
Austin, Texas 78701  
(512) 708-9310**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

*Copy to:*

**Patricia B. Tomasco  
Lee Potts  
Brown McCarroll, L.L.P.  
111 Congress Avenue, Suite 1400  
Austin, TX 78701**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)



**EXPLANATORY NOTE/DEREGISTRATION OF UNSOLD SECURITIES**

This Post-Effective Amendment No. 1 to Form S-8 Registration Statement relates to the Registration Statement on Form S-8 (File No. 333-152912) (the Registration Statement ) of Introgen Therapeutics, Inc. ( Registrant ) filed with the Securities and Exchange Commission ( SEC ) on August 8, 2008. The Registration Statement registered 1,600,000 shares of Registrant s Common Stock, par value \$0.001 per share, pursuant to Registrant s 2000 Stock Option Plan.

As a result of the delisting of Registrant s shares from the Nasdaq Capital Market and the fact that there are less than 300 holders of record of Registrant s shares as of December 31, 2008, Registrant has no obligation to continue to file, and does not plan to file, periodic reports with the SEC for any periods after January 1, 2009. Registrant filed a Form 15 on January 30, 2009 to terminate its duty to file reports under Section 13(a) and 15(d) of the U.S. Securities and Exchange Act of 1934, as amended. In accordance with the undertaking made by Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statement that remain unsold at the termination of the offering, Registrant hereby removes from registration the securities of Registrant that are registered but unsold under the Registration Statement.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant, Introgen Therapeutics, Inc., certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Austin, State of Texas, on March 6, 2009.

INTROGEN THERAPEUTICS, INC.

By: /s/ J. David Enloe, Jr.  
 J. David Enloe, Jr.  
 Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

<b>Signature</b>	<b>Title</b>	<b>Date</b>
/s/ J. David Enloe, Jr.  J. David Enloe, Jr.	Chief Executive Officer and President (Principal Executive Officer)	March 6, 2009
David G. Nance	Chairman of the Board and Director	March __, 2009
/s/ John N. Kapoor, Ph.D.  John N. Kapoor, Ph.D.	Director	March 6, 2009
/s/ William H. Cunningham, Ph.D.  William H. Cunningham, Ph.D.	Director	March 6, 2009
/s/ S. Malcolm Gillis, Ph.D.  S. Malcolm Gillis, Ph.D.	Director	March 6, 2009
Charles E. Long	Director	March __, 2009
/s/ Robert W. Pearson  Robert W. Pearson	Director	March 6, 2009